Clinical Trial - Open Label Safety Study in Acute Treatment of Migraine - Migraine

The purpose of this study is to evaluate safety and tolerability of BHV3000 (rimegepant).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Melatonin for Adolescent Migraine Prevention Study (The MAP Study).
Actual Study Start Date: *August 2, 2017
Estimated Primary Completion Date: *June 2021
Estimated Study Completion Date: *June 2021



Contact: Amy A Gelfand, MD 415-885-7832
Contact: Laura A Dapkus, NCPT 415-885-7832 Identifier: NCT03150797


For enrollment please visit

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.